Download Image
    
Share
  
Post
XAV-19 for COVID-19
2 studies with >600 patients
Hospital Icon Control
Hospital Icon XAV-19 Serious Outcome Risk
COVID-19 XAV-19 studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -45% Mortality -45% RCTs -45% RCT mortality -45% Early -1% Late -90% FavorsXAV-19 Favorscontrol
Oct 20
2023
 Gaborit et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofad525 Effect of Swine Glyco-humanized Polyclonal Neutralizing Antibody on Survival and Respiratory Failure in Patients Hospitalized With Severe COVID-19: A Randomized, Placebo-Controlled Trial
90% higher mortality (p=0.29), 106% higher ventilation (p=0.03), 5% higher ICU admission (p=0.9), and 5% higher progression (p=0.82). RCT 398 hospitalized patients with severe COVID-19 requiring low-flow oxygen therapy showing no significant difference in death or respiratory failure through day 15 with XAV-19 (a swine glyco-humanized polyclonal neutralizing antibody) c..
Oct 19
2023
 Poulakou et al., medRxiv, doi:10.1101/2023.10.09.23296726 XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2 accelerates the recovery of mild to moderate COVID-19 patients and keeps its neutralizing activity against Omicron and its subvariants
1% higher mortality (p=1) and 34% higher progression (p=0.48). RCT 293 COVID-19 patients showing no significant difference in the primary endpoint (disease aggravation within 8 days) with XAV-19, a glyco-humanized swine polyclonal antibody. While XAV-19 showed no benefit for patients requiring oxygen..